Brighton Jones LLC Sells 271 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Brighton Jones LLC decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,806 shares of the biopharmaceutical company’s stock after selling 271 shares during the period. Brighton Jones LLC’s holdings in Gilead Sciences were worth $810,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Institute for Wealth Management LLC. grew its stake in shares of Gilead Sciences by 1.9% during the 2nd quarter. Institute for Wealth Management LLC. now owns 7,551 shares of the biopharmaceutical company’s stock worth $518,000 after acquiring an additional 142 shares during the period. First Affirmative Financial Network lifted its holdings in Gilead Sciences by 3.5% during the first quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock valued at $318,000 after purchasing an additional 147 shares during the last quarter. Rathbones Group PLC boosted its position in Gilead Sciences by 3.7% during the fourth quarter. Rathbones Group PLC now owns 4,185 shares of the biopharmaceutical company’s stock worth $339,000 after purchasing an additional 150 shares during the period. MCF Advisors LLC increased its stake in shares of Gilead Sciences by 2.1% in the first quarter. MCF Advisors LLC now owns 7,348 shares of the biopharmaceutical company’s stock worth $538,000 after purchasing an additional 152 shares in the last quarter. Finally, Westside Investment Management Inc. raised its position in shares of Gilead Sciences by 0.6% in the second quarter. Westside Investment Management Inc. now owns 26,526 shares of the biopharmaceutical company’s stock valued at $1,826,000 after purchasing an additional 152 shares during the period. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Price Performance

GILD opened at $83.94 on Friday. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. The stock has a market capitalization of $104.58 billion, a P/E ratio of 233.17, a PEG ratio of 2.80 and a beta of 0.18. The stock has a 50-day moving average price of $76.95 and a 200-day moving average price of $71.26. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.40. The business had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. Equities analysts predict that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.67%. The ex-dividend date is Friday, September 13th. Gilead Sciences’s payout ratio is presently 855.56%.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. BMO Capital Markets lifted their price objective on shares of Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Robert W. Baird restated a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a research note on Thursday, June 20th. Truist Financial upped their price target on Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. Finally, Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Thursday, August 15th. Twelve investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $82.06.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. The disclosure for this sale can be found here. Insiders sold 36,847 shares of company stock valued at $3,002,940 over the last three months. Insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.